{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:49:02Z","timestamp":1769114942915,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10147-025-02727-z","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T10:41:12Z","timestamp":1740566472000},"page":"886-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal follow-up duration of cardiac function tests in patients treated with trastuzumab: an analysis using the Japanese Adverse Drug Event Report (JADER) database"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-8555","authenticated-orcid":false,"given":"Katsuya","family":"Makihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misato","family":"Tanihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieko","family":"Yoshidome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"2727_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF01518520","volume":"37","author":"GD Lewis","year":"1993","unstructured":"Lewis GD, Figari I, Fendly B et al (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255\u2013263. https:\/\/doi.org\/10.1007\/BF01518520","journal-title":"Cancer Immunol Immunother"},{"key":"2727_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1634\/theoncologist.2010-0035","volume":"16","author":"AH Boekhout","year":"2011","unstructured":"Boekhout AH, Beijnen JH, Schellens JH (2011) Trastuzumab. Oncologist 16:800\u2013810. https:\/\/doi.org\/10.1634\/theoncologist.2010-0035","journal-title":"Oncologist"},{"key":"2727_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/978-1-4615-0081-0_21","volume":"532","author":"J Albanell","year":"2003","unstructured":"Albanell J, Codony J, Rovira A et al (2003) Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532:253\u2013268. https:\/\/doi.org\/10.1007\/978-1-4615-0081-0_21","journal-title":"Adv Exp Med Biol"},{"key":"2727_CR4","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMcibr1203156","volume":"367","author":"GM Cote","year":"2012","unstructured":"Cote GM, Sawyer DB, Chabner BA (2012) ERBB2 inhibition and heart failure. N Engl J Med 367:2150\u20132153. https:\/\/doi.org\/10.1056\/NEJMcibr1203156","journal-title":"N Engl J Med"},{"key":"2727_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","volume":"7","author":"MS Ewer","year":"2010","unstructured":"Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7:564\u2013575. https:\/\/doi.org\/10.1038\/nrcardio.2010.121","journal-title":"Nat Rev Cardiol"},{"key":"2727_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","volume":"29","author":"MA Sendur","year":"2013","unstructured":"Sendur MA, Aksoy S, Altundag K (2013) Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 29:1015\u20131024. https:\/\/doi.org\/10.1185\/03007995.2013.807232","journal-title":"Curr Med Res Opin"},{"key":"2727_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215\u20131221. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1215","journal-title":"J Clin Oncol"},{"key":"2727_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.018393","volume":"10","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Bobrowski D, Zhou L et al (2021) Statin exposure and risk of heart failure after Anthracycline- or Trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc 10:e018393. https:\/\/doi.org\/10.1161\/JAHA.119.018393","journal-title":"J Am Heart Assoc"},{"key":"2727_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yjmcc.2006.04.007","volume":"41","author":"Y Kuramochi","year":"2006","unstructured":"Kuramochi Y, Guo X, Sawyer DB (2006) Neuregulin activates erbB2-dependent src\/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41:228\u2013235. https:\/\/doi.org\/10.1016\/j.yjmcc.2006.04.007","journal-title":"J Mol Cell Cardiol"},{"key":"2727_CR10","first-page":"70","volume":"16","author":"M Zeglinski","year":"2011","unstructured":"Zeglinski M, Ludke A, Jassal DS (2011) Trastuzumab-induced cardiac dysfunction: a \u2018dual-hit.\u2019 Exp Clin Cardiol 16:70\u201374","journal-title":"Exp Clin Cardiol"},{"key":"2727_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911\u2013939. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012","journal-title":"J Am Soc Echocardiogr"},{"key":"2727_CR12","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"2727_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, Kokkinidis DG, Kampaktsis PN et al (2019) Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 4:1007\u20131018. https:\/\/doi.org\/10.1001\/jamacardio.2019.2952","journal-title":"JAMA Cardiol"},{"key":"2727_CR14","volume-title":"Onco-cardiology Guideline in Japan","author":"Japanese Society of Medical Oncology and Japanese Onco-Cardiology Society","year":"2023","unstructured":"Japanese Society of Medical Oncology and Japanese Onco-Cardiology Society (2023) Onco-cardiology Guideline in Japan. Nankodo & Co., Ltd, Tokyo ((in Japanese))"},{"key":"2727_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12574-020-00502-9","volume":"19","author":"T Onishi","year":"2021","unstructured":"Onishi T, Fukuda Y, Miyazaki S et al (2021) Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. J Echocardiogr 19:1\u201320. https:\/\/doi.org\/10.1007\/s12574-020-00502-9","journal-title":"J Echocardiogr"},{"key":"2727_CR16","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"2727_CR17","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1093\/oncolo\/oyad086","volume":"28","author":"S Zhou","year":"2023","unstructured":"Zhou S, Cirne F, Chow J et al (2023) Three-year outcomes following permissive cardiotoxicity in patients on trastuzumab. Oncologist 28:e712\u2013e722. https:\/\/doi.org\/10.1093\/oncolo\/oyad086","journal-title":"Oncologist"},{"key":"2727_CR18","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1177\/10781552231193149","volume":"30","author":"SA Alowais","year":"2024","unstructured":"Alowais SA, Luk SO, Kim EB et al (2024) Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy. J Oncol Pharm Pract 30:992\u2013998. https:\/\/doi.org\/10.1177\/10781552231193149","journal-title":"J Oncol Pharm Pract"},{"key":"2727_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10549-020-06039-w","volume":"186","author":"NI Bouwer","year":"2021","unstructured":"Bouwer NI, Steenbruggen TG, van Rosmalen J et al (2021) Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring? Breast Cancer Res Treat 186:851\u2013862. https:\/\/doi.org\/10.1007\/s10549-020-06039-w","journal-title":"Breast Cancer Res Treat"},{"key":"2727_CR20","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.18632\/oncotarget.13726","volume":"8","author":"P Huang","year":"2017","unstructured":"Huang P, Dai S, Ye Z et al (2017) Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy. Oncotarget 8:2069\u20132075. https:\/\/doi.org\/10.18632\/oncotarget.13726","journal-title":"Oncotarget"},{"key":"2727_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1177\/1078155214538686","volume":"21","author":"H Mutlu","year":"2015","unstructured":"Mutlu H, Co\u015fkun H\u015e (2015) Is there any cumulative dose for trastuzumab? J Oncol Pharm Pract 21:468\u2013470. https:\/\/doi.org\/10.1177\/1078155214538686","journal-title":"J Oncol Pharm Pract"},{"key":"2727_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/tbj.12412","volume":"21","author":"B Pistilli","year":"2015","unstructured":"Pistilli B, Marcellusi A, Latini L et al (2015) Cardiotoxicity related to long-term trastuzumab therapy in metastatic breast cancer: the potential role of treatment duration and cardiac risk factors. Breast J 21:318\u2013321. https:\/\/doi.org\/10.1111\/tbj.12412","journal-title":"Breast J"},{"key":"2727_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A et al (2013) Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf 36:995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7","journal-title":"Drug Saf"},{"key":"2727_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2727_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-018-5058-6","volume":"174","author":"E Lidbrink","year":"2019","unstructured":"Lidbrink E, Chmielowska E, Otremba B et al (2019) A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Trea 174:187\u2013196. https:\/\/doi.org\/10.1007\/s10549-018-5058-6","journal-title":"Breast Cancer Res Trea"},{"key":"2727_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00392-019-01448-4","volume":"108","author":"K Ohtani","year":"2019","unstructured":"Ohtani K, Ide T, Hiasa KI et al (2019) Cardioprotective effect of renin-angiotensin inhibitors and \u03b2-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol 108:1128\u20131139. https:\/\/doi.org\/10.1007\/s00392-019-01448-4","journal-title":"Clin Res Cardiol"},{"key":"2727_CR27","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"2727_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim SB, Cort\u00e9s J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461\u2013471. https:\/\/doi.org\/10.1016\/S1470-2045(13)70130-X","journal-title":"Lancet Oncol"},{"key":"2727_CR29","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859\u20133865. https:\/\/doi.org\/10.1200\/JCO.2006.09.1611","journal-title":"J Clin Oncol"},{"key":"2727_CR30","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/ejhf.319","volume":"17","author":"H Shimokawa","year":"2015","unstructured":"Shimokawa H, Miura M, Nochioka K et al (2015) Heart failure as a general pandemic in Asia. Eur J Heart Fail 17:884\u2013892. https:\/\/doi.org\/10.1002\/ejhf.319","journal-title":"Eur J Heart Fail"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02727-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02727-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02727-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:04:23Z","timestamp":1745301863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02727-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2727"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02727-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors alone are responsible for the content and writing of this article and declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the Ministry of Health, Labour and Welfare\u2019s Ethical Guidelines for Epidemiological Studies. It also complied with the Declaration of Helsinki. This study was entirely based on an anonymized open database, and thus ethical approval was not required. This study was conducted in accordance with the terms of use of the Japanese Adverse Drug Event Report database provided by Pharmaceuticals and Medical Devices Agency.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}